Analysis of the Immune Parameters of COVID-19 Infection in Patients With Multiple Myeloma (Covimmunomm)
Analysis of the Immune Parameters Involved in the Onset and Fate of SARS-CoV-2 Infection in Patients With Multiple Myeloma (COVIMMUNOMM) COVID-19 and Multiple Myeloma
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: amandine huguet
- Phone Number: +33 0531156338
- Email: a.huguet@myelome.fr
Study Contact Backup
- Name: Chanaz Louni
- Email: c.louni@myelome.fr
Study Locations
-
-
-
Amiens, France
- CHU Amiens Sud
-
Angers, France
- CHRU Hôpital du Bocage
-
Annecy, France
- CH Annecy Genevois
-
Argenteuil, France
- Ch Victor Dupouy
-
Arras, France
- CH d'Arras
-
Auch, France
- CH Auch
-
Avignon, France
- Centre Hospitalier H.Duffaut
-
Besançon, France
- CHRU Besançon
-
Blois, France
- Centre Hospitalier Simone Veil de Blois
-
Bordeaux, France
- CHU Bordeaux-hopital haut leveque
-
Bourgoin-Jallieu, France
- Centre hospitalier Pierre Oudot
-
Brest, France
- Hôpital A.Morvan
-
Caen, France
- CHU de Caen
-
Cannes, France
- CH de Cannes
-
Castelnau-le-Lez, France
- Clinique du Parc
-
Chalon Sur Saone, France
- Centre Hospitalier William Morey
-
Chambéry, France
- Centre Hospitalier Métropole de Savoie
-
Corbeil-Essonnes, France
- Centre Hospitalier Sud Francilien
-
Créteil, France
- CHU Henri Mondor
-
Dax, France
- CH de Dax côte d'Argent
-
Dijon, France
- CHU François Mitterand
-
Grenoble, France
- Chu Grenoble
-
Grenoble, France
- Institut Daniel Hollard - Groupe Hospitalier Mutualiste de Grenoble
-
Lens, France
- CH de Lens
-
Lille, France
- Hopital Claude Huriez-CHRU LILLE
-
Limoges, France
- CHU Limoges
-
Lyon, France
- Centre Hospitalier LYON SUD
-
Mont-de-Marsan, France
- GHT des Landes
-
Montpellier, France
- CHU Saint Eloi
-
Mulhouse, France
- Hôpital E. Muller
-
Nancy, France
- Hôpitaux de Brabois - CHRU de Nancy
-
Nantes, France
- CHRU Nantes
-
Nice, France
- Hôpital Archet 1
-
Paris, France
- Hôpital Pitié-Salpêtrière
-
Paris, France
- Hôpital Necker Enfants malades
-
Paris, France
- Hopital Saint Antoine
-
Paris, France
- Hôpital Cochin
-
Poitiers, France
- CHU Poitiers
-
Pontoise, France
- CH René Dubos
-
Reims, France
- CHU de Reims
-
Rennes, France
- CHU Pontchaillou
-
Roubaix, France
- CH Roubaix
-
Rouen, France
- Centre Henri Becquerel
-
Saint brieuc, France
- Centre Hospitalier Yves le Foll
-
Saint-Priest, France
- Institut de Cancérologie Lucien Neuwirth
-
Saint-Quentin, France
- Centre Hospitalier
-
Strasbourg, France
- ICANS
-
Tarbes, France
- CH Tarbes
-
Toulouse, France
- CHU Toulouse
-
Tours, France
- CHRU Bretonneau
-
Valenciennes, France
- CH de Valenciennes
-
Vannes, France
- CH Bretagne Atlantique Vannes et Auray-P.Chubert
-
Versailles, France
- CHV André Mignot
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients with a multiple myeloma and a documented COVID19 (by RT-PCR, thoracic TDM, and/or antigenix test).
- Patients having received the information to participate in the research and having expressed their non-opposition
- Patients with social security insurance or equivalent
Exclusion Criteria:
- Patients without multiple myeloma
- Patients without COVID19
- Patients under juridical protection guardianship, or tutelage measure
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: blood samples
4 blood samples per patient maximum (at diagnosis of covid19, during intensive care if applicable, at revecory of covid 19 and 6 months after recovery.
|
maximum 4 blood samples analyses per patient.
At diagnosis of covid 19, in intensif care (if applicable), at covid19 recovery and 6 months after recovery
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Characterize the immune laboratory parameters of Multiple Myeloma patients at the start of infection with COVID-19
Time Frame: up to one month following COVID-19 diagnosis
|
gammaglobulin measurements in g/L
|
up to one month following COVID-19 diagnosis
|
|
Characterize the immune laboratory parameters of Multiple Myeloma patients at the cure of COVID-19
Time Frame: one month following COVID-19 diagnosis
|
gammaglobulin measurements in g/L
|
one month following COVID-19 diagnosis
|
|
Characterize the immune laboratory parameters of Multiple Myeloma patients at the start of infection with COVID-19
Time Frame: up to one month following COVID-19 diagnosis
|
lymphocytes counts in g/l
|
up to one month following COVID-19 diagnosis
|
|
Characterize the immune laboratory parameters of Multiple Myeloma patients at the cure of COVID-19
Time Frame: one month following COVID-19 diagnosis
|
lymphocytes counts in g/l
|
one month following COVID-19 diagnosis
|
|
Characterize the immune laboratory parameters of Multiple Myeloma patients at the start of infection with COVID-19
Time Frame: up to one month following COVID-19 diagnosis
|
number of cells B, T, and NK actived and inhibited
|
up to one month following COVID-19 diagnosis
|
|
Characterize the immune laboratory parameters of Multiple Myeloma patientsat the cure of COVID-19
Time Frame: one month following COVID-19 diagnosis
|
number of cells B, T, and NK actived and inhibited
|
one month following COVID-19 diagnosis
|
|
Correlation of patient immune function with death or development of protective immunity
Time Frame: up to 6 months following COVID-19 diagnosis
|
number of death
|
up to 6 months following COVID-19 diagnosis
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of patient with protective immune response
Time Frame: before the reintroduction of MM treatments, and 6 months later to evaluate if those treatments
|
T cell repertoire sequencing looking for SARS-CoV-2- specific T cells, and serologies
|
before the reintroduction of MM treatments, and 6 months later to evaluate if those treatments
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Hervé Avet Loiseau, PU-PH, Intergroupe Francophone du Myelome
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- COVID-19
- Multiple Myeloma
- Neoplasms, Plasma Cell
Other Study ID Numbers
Other Study ID Numbers
- IFM 2020-08
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.